Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.0B
21M shares
52-week range
$30.75 – $50.88
76% from low
Sector
GLASS PRODUCTS, MADE OF PURCHASED GLASS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.39B | $1.23B | $1.31B | $1.44B | $1.42B | $1.36B | $1.40B |
| Cost of revenue | $1.11B | $1.08B | $955.1M | $1.01B | $1.11B | $1.04B | $996.9M | $1.09B |
| Gross profit | $293.6M | $304.0M | $275.7M | $302.4M | $335.3M | $372.6M | $364.1M | $319.5M |
| Gross margin | 20.9% | 21.9% | 22.4% | 23.0% | 23.3% | 26.3% | 26.8% | 22.7% |
| R&D | $19.5M | $16.6M | $15.3M | $17.3M | $25.5M | $30.3M | $29.0M | $0 |
| Operating income | $67.3M | $87.8M | $25.5M | $22.0M | $125.8M | $133.8M | $118.1M | $84.5M |
| EBITDA | $120.2M | $119.6M | $139.6M | $152.0M | $168.2M | $187.8M | $184.9M | $141.4M |
| Net income | $45.7M | $61.9M | $15.4M | $3.5M | $104.1M | $99.6M | $85.1M | $54.1M |
| Net margin | 3.3% | 4.5% | 1.3% | 0.3% | 7.2% | 7.0% | 6.2% | 3.9% |
| EPS (diluted) | 1.63 | 2.32 | 0.59 | 0.14 | 4.64 | 4.51 | 3.89 | 2.52 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $1.4B | $2.86 | $2.75–$2.96 | 2 |
| 2028 | $1.5B | $3.70 | $3.68–$3.73 | 1 |
Forward consensus · source: Financial Modeling Prep
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.
www.apog.comNo one on the platform currently holds APOG.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 190,517 | $6.4M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-14 | $0.2700 | 2026-07-29 |
| 2026-05-13 | $0.2700 | 2026-05-28 |
| 2026-02-03 | $0.2700 | 2026-02-18 |
| 2025-10-29 | $0.2600 | 2025-11-13 |
| 2025-07-16 | $0.2600 | 2025-07-31 |
| 2025-05-13 | $0.2600 | 2025-05-28 |
| 2025-01-28 | $0.2600 | 2025-02-12 |
| 2024-10-22 | $0.2500 | 2024-11-06 |
| 2024-07-10 | $0.2500 | 2024-07-25 |
| 2024-05-20 | $0.2500 | 2024-06-05 |
No one on the platform has traded APOG yet.
| +0.00% |
| $725M |
| — |
| GLDDGreat Lakes Dredge & Dock Corporation | $17.00 | +0.00% | $1.1B | — |
| NATNordic American Tankers Limited | $5.78 | -1.20% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2024-01-29 |
| $0.2500 |
| 2024-02-14 |
| 2023-10-23 | $0.2400 | 2023-11-08 |
Trading at 19.7× earnings vs its 14.6× historical median P/E.
Fair value ≈ $34.15 · price $46.10 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$APOG Why Apogee Enterprises Stock Is Skyrocketing Today https://marketwirenews.com/stock/apog/news/why-apogee-enterprises-stock-is-skyrocketing-today-7580248848650193.html?utm_source=stocktwits
View on StockTwits ↗$APOG Expected US Company Earnings on Friday, June 26th, 2026 https://marketwirenews.com/stock/apog/news/expected-us-company-earnings-on-friday-june-26th-202-6728045924126439.html?utm_source=stocktwits
View on StockTwits ↗$APOG Apogee Enterprises Reports Fiscal 2027 First Quarter Results https://marketwirenews.com/stock/apog/news/apogee-enterprises-reports-fiscal-2027-first-quarter-7223310347195300.html?utm_source=stocktwits
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-6-26-apogee-enterprises-inc-stock/ $APOG Apogee Enterprises Earnings Transcript
View on StockTwits ↗$APOG Q1 '27 Earnings Results & Recap Apogee Enterprises Inc. reaffirms fiscal 2027 guidance for net sales of $1.38 billion to $1.43 billion and adjusted diluted EPS of $2.70 to $3.25. With the Kalwall acquisition, net sales are expected to be $1.43 billion to $1.48 billion.
View on StockTwits ↗Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $ACAD, $APOG, $CNVS.
View on StockTwits ↗$APOG (+9.1% pre) Apogee (NASDAQ:APOG) Delivers Impressive Q2 CY2026, Stock Soars https://ooc.bz/l/106324
View on StockTwits ↗$APOG hey @Olddrache Can you pls post options flow 10 to 20 mins before close today? Thanks!
View on StockTwits ↗#earnings after the close on Thursday, June 25, 2026, and before the open on Friday, June 26, 2026 https://www.earningswhispers.com/calendar $FDXF $APOG $QMCO $WSE $AOUT
View on StockTwits ↗$APOG hey @Olddrache, is it okay if you can post flow before close the same time like today (around the equivalent of 3:54 pm) or 3:55 but for tomorrow for this stock? Thanks so much!
View on StockTwits ↗New research today on @apogeeglass $APOG #sidotiresearch Read note: http://dlvr.it/TTBhzv #investing #smallcap #microcap
View on StockTwits ↗Wall St is expecting 0.67 EPS for $APOG Q2 [Reporting 09/22 BMO] http://www.estimize.com/intro/apog?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$ABBV: AbbVie is trading higher after agreeing to buy Apogee Therapeutics for $135.11/share in cash, valuing $APGE at about $10.9 bln. The deal deepens ABBV’s immunology pipeline, but investors will be watching the price tag, clinical risk, and long path to EPS accretion. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/abbvie-catches-apogee-fever-109b-deal-expands-immunology-and-asthma-pipeline?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $APOG #Abbvie $LLY $JNJ #Apogee #biotech #pharma #Immunology #asthma #healthcare #health
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.